ACPE Continuing Pharmacy Education

his program has been planned and implemented in accordance with the policies of the Accreditation Council on Pharmacy Education (ACPE) through the joint sponsorship of the Oregon State University College of Pharmacy and the Oregon Society for Health-System Pharmacists (OSHP). The Oregon State University College of Pharmacy is accredited by the Accreditation Council on Pharmacy Education as a provider of continuing pharmacy education. 

Pharmacists and Pharmacy Technicians will receive ACPE Continuing Education Credit. An NABP e-Profile ID is required to receive CPE hours. An NABP e-Profile ID can be obtained at MyCPEMonitor.net. Statement of Credit shall be issued only after successful completion of the program. Successful completion is defined as: 1) Attending, in its entirety, the CPE activity or activities; 2) Participation in the pre-test administered by the presenter; 3) Completion of the online activity evaluation and post-test located at: http://pharmacy.oregonstate.edu/ce within 14 days of program attendance. 

Statements of Credit will be uploaded to each participant’s NABP e-profile automatically within 48 hours of successful program completion. It is the participant’s responsibility to complete the online components within 14 days of program attendance to ensure awarding of credit. It is the participant's responsibility to check CPE Monitor and ensure credits have successfully uploaded. 

Target Audience: Pharmacists and Pharmacy Technicians
Total Credits Available: 10.5 contact hours for up to 1.05 CEUs
Conflict of Interest Disclosures: None of the speakers or planners for this program have any financial relationships with ineligible companies to disclose.

Title: Demystifying Pharmacist Prescribing in Oregon
UAN: 0036-9999-26-200-L04-P/T
Date & Time: 4/24/26, 1:05-2:05 pm
Speakers: Gary Runyon, PharmD, RPh, Oregon Board of Pharmacy, Executive Director; Courtney Sellers, PharmD
Activity-Type: Knowledge-based
Credit Hours: 1.0
Learning Objectives:

1. Review the statutory and regulatory framework governing pharmacist prescriptive authority in Oregon, specifically distinguishing between the broad authorities granted under ORS 689 and the specific requirements and prohibitions set forth in OAR Chapter 855 Division 115.
2. Distinguish between the structure and function of the Formulary, Statewide Drug Therapy Management Protocol, and Standing Order to determine the appropriate pathway for various patient-care services.
3. Examine the essential requirements for post-diagnostic and protocol-based services, such as clinical inclusion and exclusion criteria, general applicability, and specific idiosyncratic requirements for medications such as insulin refills, smoking cessation aids, oral contraceptives, etc.
4. Review recently adopted statewide protocols and explore emerging local, regional, and federal developments—such as West Coast Health Alliance recommendations and 2026 legislative concepts—to understand their potential impact on the landscape of pharmacist prescribing in Oregon.
5. Discuss pathways for professional engagement by identifying how to attend PHPFAC meetings virtually, provide feedback on existing rules, and submit new protocol concepts for Board consideration.

Title: Don’t Blame Me, Blame ChatGPT: Recognizing Cognitive Debt in Pharmacy Education
UAN: 0036-9999-26-201-L99-P/T
Date & Time: 4/24/26, 2:10-3:10 pm
Speakers: Maddie Fry, PharmD, BCACP, Pacific University School of Pharmacy, Associate Professor, Assistant Dean for Experiential Education; Ryan Gibbard, PharmD, BCPS, Pacific University School of Pharmacy, Associate Professor
Activity-Type: Knowledge-based
Credit Hours: 1.0
Learning Objectives:

1. Recognize behaviors that put learners at higher risk of cognitive offloading and cognitive debt
2. Identify strategies to mitigate cognitive debt among pharmacy learners
3. Recognize examples of cognitive offloading that modern learners may demonstrate

Title: Clinical Pearls – Track I
UAN: 0036-9999-26-202-L01-P/T
Date & Time: 4/24/26, 4:40-5:40 pm
Speakers: Trixy Angelie Pilando Ibis, PharmD, Roseburg VA Health Care System, PGY-1 Pharmacy Resident; Mike Millard, PharmD, MS, FOSHP, Pacific University School of Pharmacy; Margaux Groff, PharmD, Dept. of Veterans Affairs, Eugene Health Care Clinic, PGY-1 Resident; Rosalind Wong, PharmD, Legacy Health – Emanuel Medical Center, PGY-1 Pharmacy Resident
Activity-Type: Knowledge-based
Credit Hours: 1.0
RPh Learning Objectives:

1. (Trixy Angelie Pilando Ibis) Describe the role and effectiveness of metformin as an off-label treatment for prevention and treatment in antipsychotic-induced weight gain and metabolic disturbances in patients with psychiatric disorders.
2. (Mike Millard) Define Standard of Care Regulation basic requirements
3. (Mike Millard) Describe the current status of Standard of Care Regulation in the US
4. (Margaux Groff) Identify medication that can cause false CGM readings
5. (Margaux Groff) Evaluate CGM readings given potential interfering medications
6. (Rosalind Wong) Summarize evidence-based guideline updates for the management of patients presenting with acute ischemic stroke
7. (Rosalind Wong) Compare changes between the 2019 and 2026 AHA/ASA guidelines for acute ischemic stroke

CPT Learning Objectives:

1. (Trixy Angelie Pilando Ibis) Describe the role and effectiveness of metformin as an off-label treatment for prevention and treatment in antipsychotic-induced weight gain and metabolic disturbances in patients with psychiatric disorders.
2. (Mike Millard) Define Standard of Care Regulation basic requirements
3. (Mike Millard) Describe the current status of Standard of Care Regulation in the US
4. (Margaux Groff) Recall risks associated with false CGM readings
5. (Margaux Groff) Name which CGMs can have false readings
6. (Rosalind Wong) Summarize evidence-based guideline updates for the management of patients presenting with acute ischemic stroke
7. (Rosalind Wong) Compare changes between the 2019 and 2026 AHA/ASA guidelines for acute ischemic stroke

Title: Clinical Pearls – Track II
UAN: 0036-9999-26-203-L01-P/T
Date & Time: 4/24/26, 4:40-5:40 pm
Speakers: Trang Tran, PharmD, Roseburg VA Health Care System, PGY-1 Pharmacy Resident; Annie Saefong, PharmD, Roseburg VA Health Care System, PGY-1 Pharmacy Resident; Zachary McCall, PharmD, MBA, BCPS, BCACP, FOSHP, Legacy Health, Ambulatory Pharmacy Services Director; Young Yoon Ham, PharmD, BCIDP, OHSU, Infectious Disease and Antibiotic Allergy Pharmacist
Activity-Type: Knowledge-based
Credit Hours: 1.0
RPh Learning Objectives:

1. (Trang Tran) Define and differentiate the various types of prescribing cascades
2. (Trang Tran) Assess whether a prescribing cascade represents appropriate or potentially inappropriate therapy
3. (Annie Saefong) Recognize the potential for GLP-1 receptor agonists in substance use disorders
4. (Annie Saefong) Explain the mechanism of action of GLP-1 receptor agonists in substance use disorders
5. (Zachary McCall) Identify the value of a pharmacy supported, patient-centric care model for medication support
6. (Zachary McCall) Describe how an integrated health system can benefit from a specialty pharmacy care model
7. (Young Yoon Ham) Compare the PK/PD rationale for twice- vs three-times-daily dosing of amoxicillin-clavulanate.
8. (Young Yoon Ham) Select appropriate patients for three-times-daily dosing of amoxicillin-clavulanate based on clinical factors. 

CPT Learning Objectives:

1. (Trang Tran) Define and differentiate the various types of prescribing cascades
2. (Trang Tran) Assess whether a prescribing cascade represents appropriate or potentially inappropriate therapy
3. (Annie Saefong) Recognize the potential for GLP-1 receptor agonists in substance use disorders
4. (Annie Saefong) Differentiate different uses and indications of GLP-1 receptor agonists
5. (Zachary McCall) Describe the pharmacy technician role in supporting a specialty care model
6. (Zachary McCall) Describe the pharmacy technician role in health system sustainability initiatives
7. (Young Yoon Ham) Compare the PK/PD rationale for twice- vs three-times-daily dosing of amoxicillin-clavulanate.
8. (Young Yoon Ham) Select appropriate patients for three-times-daily dosing of amoxicillin-clavulanate based on clinical factors.

Title: Oregon Indian Country: Tribal Sovereignty’s Impact on Health Care
UAN: 0036-9999-26-204-L99-P/T
Date & Time: 4/25/26, 8:10-9:10 am
Speakers: Claymore Kills First, PharmD, OHSU, Research Assistant Professor, Oncology Pharmacist
Activity-Type: Knowledge-based
Credit Hours: 1.0
State Requirement: Cultural Competence
Learning Objectives:

1. Recognize historical and cultural factors that influence healthcare utilization among Tribal members
2. Describe how Tribal sovereignty influences healthcare delivery in Oregon Indian Country
3. Identify strategies to support culturally responsive care and collaboration with Tribal members
4. Summarize collaborative research initiatives with Tribal partners at the OHSU Knight Cancer Institute aimed at improving cancer care access and outcomes for Tribal members 

Title: Emergency Preparedness for Ambulatory & Health‑System Pharmacists Ensuring Continuity of Care, Patient Safety, and Community Resilience
UAN: 0036-9999-26-205-L05-P and 0036-9999-26-206-L05-T
Date & Time: 4/25/26, 12:30-2:00 pm
Speakers: Amy Cervan, PharmD, Rogue Community Health, Senior Director of Pharmacy; Amber Taylor, PharmD, Rogue Community Health, Director of Pharmacy
Activity-Type: Application-based for RPh; Knowledge-based for CPT
Credit Hours: 1.5
State Requirement: Patient Safety
RPh Learning Objectives:

1. Describe how ambulatory and health system pharmacists support community health and continuity of care during emergencies
2. Apply practical approaches to maintain medication access and chronic disease stability when systems, supply chains, or infrastructure fail
3. Explain how pharmacists support community resilience before, during, and after emergencies
4. Recognize opportunities for pharmacists to participate in community-level emergency response efforts

CPT Learning Objectives:

1. Identify how pharmacy technicians can maintain medication access and support vulnerable patients in the community during emergencies
2. Describe technician responsibilities that strengthen community continuity of care during disasters or system outages
3. Explain how pharmacy technicians assist with accurate information gathering and manual workflows during outages or downtime
4. Recognize opportunities for pharmacy technicians to participate in community-level emergency response efforts 

Title: PrEPared in Primary Care: Putting PrEP into Practice
UAN: 0036-9999-26-207-L01-P and 0036-9999-26-208-L01-T
Date & Time: 4/25/26, 2:30-3:30 pm
Speakers: Jessica Potter, PharmD, BCACP, Legacy Health, Ambulatory Care Pharmacist
Activity-Type: Application-based for RPh; Knowledge-based for CPT
Credit Hours: 1.0
RPh Learning Objectives:

1. Identify individuals who may benefit from HIV PrEP
2. Compare and contrast the two long-acting injectable therapies that are indicated for HIV PrEP
3. Identify key counseling points when prescribing lenacapavir subcutaneous injection therapy
4. Given a patient case, recommend monitoring requirements while on HIV PrEP therapy

CPT Learning Objectives:

1. Describe dosing schedule for the two long-acting injectable therapies that are indicated for HIV PrEP
2. Compare and contrast the two long-acting injectable therapies that are indicated for HIV PrEP
3. Describe key monitoring and follow-up needs for patients receiving HIV PrEP

Title: Rewriting Disease: Gene Therapy and Gene Editing in Today’s Pharmacy
UAN: 0036-9999-26-209-L01-P/T
Date & Time: 4/25/26, 2:30-3:30 pm
Speakers: Nicola Carter, PhD, Pacific University School of Pharmacy, Chair and Associate Professor of Pharmaceutical Sciences; Sigrid C. Roberts, PhD, Pacific University, Professor
Activity-Type: Knowledge-based
Credit Hours: 1.0
Learning Objectives:

1. Describe the basic principles of gene editing versus gene therapy
2. Discuss the promises and challenges of gene editing for pharmaceutical treatment strategies
3. List currently available treatments based on gene editing

Title: GDMT Without Gaps: Building and Maintaining Optimal Therapy Across the Patient Journey
UAN: 0036-9999-26-210-L01-P and 0036-9999-26-211-L01-T
Date & Time: 4/25/26, 3:45-4:45 pm
Speakers: Alyssa Rabon, PharmD, BCCCP, OHSU, Advanced Heart Failure and Transplant Pharmacist
Activity-Type: Application-based for RPh; Knowledge-based for CPT
Credit Hours: 1.0
RPh Learning Objectives:

1. Apply evidence-based practices to safely initiate and titrate guideline directed medical therapy across the patient care continuum
2. Evaluate barriers during transitions of care and opportunities for meaningful pharmacist’s interventions
3. Design patient-centered medication regimens that optimize heart failure patient outcomes

CPT Learning Objectives:

1. Discuss evidence-based practices used to safely initiate and titrate guideline directed medical therapy across the patient care continuum
2. Evaluate barriers during transitions of care and opportunities for meaningful pharmacist’s interventions
3. List patient-centered medication regimens that optimize heart failure patient outcomes

Title: FDA-Approved Anti-Amyloid Therapies for Alzheimer’s Disease: New Evidence and Practice Updates
UAN: 0036-9999-26-212-L01-P and 0036-9999-26-213-L01-T
Date & Time: 4/25/26, 3:45-4:45 pm
Speakers: Marketa Marvanova, PharmD, PhD, BCGP, BCPP, FASCP, Pacific University School of Pharmacy, Dean and Professor
Activity-Type: Application-based for RPh; Knowledge-based for CPT
Credit Hours: 1.0
RPh Learning Objectives:

1. Summarize the mechanisms of action, place in therapy, and available dosage formulations of FDA-approved anti-amyloid therapies for Alzheimer’s disease
2. Summarize eligibility criteria for initiating lecanemab and donanemab
3. Describe the latest clinical trial findings and regulatory updates related to lecanemab and donanemab, including dosing strategies and monitoring considerations
4. Implement safety workflows for risk mitigation and monitoring of amyloid-related imaging abnormalities (ARIA), infusion-related reactions, and injection-site reactions in patients receiving lecanemab or donanemab

CPT Learning Objectives:

1. Summarize the mechanisms of action, place in therapy, and available dosage formulations of FDA-approved anti-amyloid therapies for Alzheimer’s disease
2. Recognize general eligibility considerations for patients receiving lecanemab or donanemab
3. Identify recent updates related to lecanemab and donanemab, including administration schedules, and dosing intervals
4. Support safe medication-use processes by identifying important safety considerations, including amyloid-related imaging abnormalities (ARIA), infusion-related reactions, and injection-site reactions and associated management

Title: Oregon Board of Pharmacy Law Update
UAN: 0036-9999-26-214-L03-P/T
Date & Time: 4/26/26, 8:05-9:05 am
Speakers: Gary Runyon, PharmD, RPh, Oregon Board of Pharmacy, Executive Director; Jane Lee, Compliance Officer
Activity-Type: Knowledge-based
Credit Hours: 1.0
State Requirement: Law
Learning Objectives:

1. Develop effective strategies to organize and search reference materials, including those on the Board of Pharmacy’s website
2. Review current and proposed structure of OAR Chapter 855 Board of Pharmacy Rules to better understand rules framework
3. Discuss recent legislative changes, new rules, and proposed rule amendments that affect pharmacy practice in Oregon specifically for Pharmacists, Pharmacy Interns, Certified Oregon Pharmacy Technicians, and Pharmacy Technicians
4. List common observations discovered during routine inspections
5. Review available pathways to communicate with and provide feedback to the Board of Pharmacy

Title: From Guidelines to Practice: An Update on High Blood Pressure Management
UAN: 0036-9999-26-215-L01-P and 0036-9999-26-216-L01-T
Date & Time: 4/26/26, 9:10-10:10 am
Speakers: Abby Frye, PharmD, BCACP, Providence Medical Group, Clinical Pharmacy Specialist
Activity-Type: Application-based for RPh; Knowledge-based for CPT
Credit Hours: 1.0
RPh Learning Objectives:

1. Summarize the 2025 ACC/AHA High Blood Pressure Guidelines
2. Review the PREVENT Risk Calculator to estimate cardiovascular risk and guide treatment decisions
3. Apply new recommendations regarding treatment goals, initiation of therapy, laboratory monitoring, and non-pharmacologic interventions in case-based scenarios

CPT Learning Objectives:

1. Summarize the 2025 ACC/AHA High Blood Pressure Guidelines
2. Recognize the PREVENT Risk Calculator as a tool to establish cardiovascular risk
3. Identify single-pill combinations (SPCs) that can be used to optimize pharmacologic treatment for hypertension

Title: Considerations for Safe Prescribing in Older Adults
UAN: 0036-9999-26-217-L05-P and 0036-9999-26-218-L05-T
Date & Time: 4/26/26, 10:30-11:30 am
Speakers: Katie Bowden, PharmD, Roseburg VA Health Care System, Palliative Care Clinical Pharmacist
Activity-Type: Application-based for RPh; Knowledge-based for CPT
Credit Hours: 1.0
State Requirement: Patient Safety
RPh Learning Objectives:

1. Recognize challenges for safe medication use and potentially inappropriate medications
2. Identify safety strategies and resources available to evaluate clinically important prescribing concerns
3. Apply concepts using a safety protocol for deprescribing through a patient case

CPT Learning Objectives:

1. Recognize challenges for safe medication use and potentially inappropriate medications
2. Identify safety strategies and resources available to evaluate clinically important prescribing concerns
3. Discuss concepts using a safety protocol for deprescribing